Novozymes reports 4% increase in sales in Q1

Published: 26-Apr-2013
Finance Pharmaceutical

Biopharma sales rise by 22%


Danish biotechnology company Novozymes, which is focused on enzyme production, reported a 4% rise in sales to DKK2.8bn (US$496m; €381m) in the first quarter of 2013. Pre-tax profit was flat at DKK661m.

Enzyme Business sales were DKK2.5bn, up by 2% compared with the first quarter of 2012.

Biopharma sales increased by 22% owing to good underlying development in the albumin business and interest in the albufuse technologies. Sales of hyaluronic acid remained at a low level in Q1 pending customer product testing, the firm said.

Sales in Europe, the Middle East and Africa increased by 7%, and by the same percentage in the Asia Pacific region. Latin America also saw positive growth of 8%.

By contrast, sales dipped by 1% in the US.

‘Overall, the first quarter was as expected. We're off to a satisfactory start in 2013, and we maintain the full-year outlook,’ said Peder Holk Nielsen, President and CEO.

‘Organic sales growth came in at the lower end of our full-year guidance, and we remain confident that it will pick up during the course of the year.’

  • Companies:
  • Novozymes
See more

You may also like

Finance

Novo companies announce enzyme collaboration for biopharmaceuticals

Read more
Enzymes used in biopharmaceutical processing make up a small part of the 15bn DKK ($2.3bn) market for specialty enzymes, with yearly expected growth rates in the high-single digits

Trending Articles

  1. Cleancube multi: Guardtech’s container facilities support NHS aseptic pharmacies Award-winning mobile cleanrooms offer fast, flexible solutions for facility upgrades
  2. Pfizer gains European Commission approval for haemophilia A and B drug, Hympavzi The subcutaneous therapeutic is the first and only anti-tissue factor pathway inhibitor approved for the treatment of haemophilia A or B, and is available in an auto-injector format
  3. Dual-chamber packaging systems as a simplification factor in the supply chain Dual-chamber packaging solutions could represent a new frontier also to package parenteral drugs, simplifying the supply chain through reconstitution, potentially making logistics more flexible and efficient, says Cecilia Bassi, Product Manager at Bormioli Pharma
  4. Syndax Pharmaceuticals' leukaemia drug Revuforj bags FDA approval The therapeutic is the first and only menin inhibitor to gain FDA approval for acute relapsed or refractory acute leukaemia
  5. AbbVie's Elahere approved for platinum-resistant ovarian cancer by the European Commission Elahere is the first FRα-targeting antibody-drug conjugate (ADC) to be approved in Europe for platinum-resistant ovarian cancer

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Finance

Novo companies announce enzyme collaboration for biopharmaceuticals

Enzymes used in biopharmaceutical processing make up a small part of the 15bn DKK ($2.3bn) market for specialty enzymes, with yearly expected growth rates in the high-single digits
Ingredients

Novozymes reports a good year in 2014

Sales of enzyme solutions and albumin for the manufacture and formulation of pharma ingredients up by 10%
You need to be a subscriber to read this article.
Click here to find out more.
Pharmaceutical

Diversity aids a biotech boom

The biotech sector is boosted by invention and shows no sign of slowing. Biopharmaceutical pipelines are broadening and production techniques improving. Susan Birks reports
Research & Development

Novozymes Biopharma enters agreement with leading vaccine company

To conduct research on a novel subunit vaccine complex based on albumin fusion technology
Research & Development

Novozymes Biopharma to offer drug-albumin conjugation platform with ThioLogics

New partnership to offer serum-stable drug-albumin conjugation capability
Manufacturing

GSK uses Novozymes\' Veltis half-life extension technology in once-weekly diabetes drug

Novozymes technology used in recently approved Eperzan type 2 diabetes treatment
Ingredients

Good outlook for Novozymes after eventful 2013

Strong increase in sales of products for the manufacture of pharmaceuticals
Subscribe now